We use cookies to provide you with the best of services and customized features. By continuing to browse this website, you give your informed consent to our Cookie Policy.
Sirnaomics, Inc. announced that FDA had granted orphan drug designation to its siRNA therapeutic candidate, STP705, for the treatment of Hepatocellular Carcinoma (HCC).
